Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2002 Canadian Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (494)	3/10/2002 5:41:42 PM
From: Al Collard	Respond to of 1590

Hi TexasDude, A little info on YM Biosciences. Hope this helps. Regards, Al As of fiscal year end June 30, 2001 there were 12,973,094 common shares of the company outstanding (on a fully diluted basis there were 16,973,951 common shares outstanding). While the company’s common stock is not currently traded on any stock exchange, the company is a reporting issuer in certain jurisdictions in Canada. ymbiosciences.com

To: Arthur Radley who wrote (494)	3/10/2002 5:59:27 PM
From: Al Collard	Read Replies (1) \| Respond to of 1590

YM BioSciences Inc. files amended and restated preliminary prospectus to extend initial public offering of Class B Preferred Shares, Series 1 to include Quebec MISSISSAUGA, ON, March 8 /CNW/ - YM BioSciences Inc. today announced that it has filed an amended and restated Preliminary Prospectus with Canadian securities regulatory authorities in certain provinces in connection with a public offering by the Company of its Class B Preferred Shares, Series 1. The principal reason for amending and restating the preliminary prospectus was to extend the offer into the Province of Quebec. The Company does not intend to complete a listing of its common shares at this time. However, it is anticipated that the preferred shares will automatically convert into common shares one year after they are issued, so long as the Company has obtained a listing for the common shares on a prescribed stock exchange within the meaning of Canadian tax laws. In addition, earlier or later conversion may occur in certain specified circumstances. The Class B Preferred Shares will be offered on an agency basis through Canaccord Capital Corporation in Canada and Canaccord Capital (Europe) Limited elsewhere. All of the Class B Preferred Shares, Series 1, offered in the offering are being issued and sold by the Company. The net proceeds will be used primarily to develop the Company's licensed oncology products. YM BioSciences Inc., a Canadian company incorporated in 1994, licenses and develops innovative cancer therapeutics. It partners with biotechnology and pharmaceutical companies, as well as with drug discovery organizations and academic institutes, to develop cancer treatment applications of their novel agents and technologies. The Company in-licenses drug products and takes them through the development process, including regulatory affairs and clinical research, toward preparation for regulatory approval. YM BioSciences is building a product portfolio of cancer therapeutics across a variety of technologies and indications. YM BioSciences currently has a total of six cancer products in clinical development. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such jurisdiction.

To: Arthur Radley who wrote (494)	3/21/2002 8:40:46 AM
From: Al Collard	Read Replies (1) \| Respond to of 1590

AXP-t...in the news: Axcan Prices Share Offering newswire.ca

To: Arthur Radley who wrote (494)	3/25/2002 9:16:55 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Announces that the Underwriters Exercised the Over-Allotment Option newswire.ca

To: Arthur Radley who wrote (494)	3/26/2002 12:56:44 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Small Cap Digest Trading Alert: Axcan Pharmaceuticals Our trading alert is on Axcan Pharmaceuticals (AXCA) a company SmallCap Digest subscribers have heard of before. Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of gastrointestinal diseases and disorders. The company has a very impressive drug pipeline currently developing five products for nine indications, eight of which are in phase II or III studies. In 2001 the company produced $104.55 million in revenue and expects $129 mill in 2002 and $142 in 2003. Earnings per share were $0.31 in 01, est of $0.47 in 02 and $0.56 in 03. The reason for the trading alert is based on three related events. Secondary Filing NDA For Barrett's Esophagus Wall Street Analysts Secondary Offering Axcan just recently filed to sell 4.5 million shares to help pay for the acquisition of Enteris and bulk up the balance sheet. The offering was very warmly received with the company selling 5 million shares at $11.50 per share. In addition, the underwriters of the secondary offering exercised their over-allotment option and purchased from Axcan an additional 750,000 common shares. In a week when biotechs were getting hammered, it was very impressive that Axcan was able to price the offering at such a minimal discount to the market and also having such strong demand. Selling 5,750,000 shares brought roughly $66 million of which approximately $12 million will be used to pay off the Enteris acquisition. That leaves about $54 million in the bank which will be earmarked for sales and marketing of newly approved drugs and possibly an acquisition. NDA For Barrett's Esophagus Axcan is expected to file a new drug application (NDA) for the treatment of Barrett's Esophagus with Photofrin. The filing is expected before the end of March with approval coming in September of this year. The secondary offering gives Axcan a nice war chest to fund the sales and marketing of Photofrin for Barrett's Esophagus. The fact that Axcan raised $66 million leads us to believe everything is on track for the NDA filing. This filing should pop the stock anywhere from 10%-20%. Wall Street Analysts J.P. Morgan, Thomas Weisel Partners LLC, UBS Warburg LLC, National Bank Financial Inc. and SunTrust Capital Markets, Inc. served as the managers of the offering. All of them currently have coverage on Axcan except for UBS Warburg which means there is a very high likelihood that the investment bank initiates coverage. In case our subscribers forgot, fees for banks equal coverage for companies. Currently, the estimates the analysts have for Axcan do not include additional FDA approvals. Once the NDA is filed perhaps the analysts will have the heart to upgrade or even send out some positive notes on the company. JP Morgan and SunTrust Capital already have issued some positive notes early this am and it will be a matter of time before the rest follow. Conclusion The catalyst is an NDA filing which will prompt analysts' upgrades and the initiation of coverage by UBS. The UBS coverage may come before or after the filing but due to its involvement with the secondary it would be almost impossible for them not to give Axcan coverage. The company itself is poised to do very well in the future but this trading alert is based on events we feel are in the near future. Some SmallCap Digest subscribers may decide this is a long term hold as opposed to a trading alert. Either way the floor on this stock should be in the $11.50-$12.00 level. Considering that the secondary was priced at $11.50 it would take a catastrophic event for the stock to go below that level. A break above the 50 day moving average at around $13.00 dollars will form a cup and handle chart pattern. The combination of an NDA filing and a barrage of positive analyst notes will help push Axcan past its 52 week high of $14.58.

To: Arthur Radley who wrote (494)	4/3/2002 1:55:40 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan to Acquire the Company Laboratoire du Lactéol du Docteur Boucard, in France - Second acquisition to double revenues in Western Europe newswire.ca

To: Arthur Radley who wrote (494)	4/11/2002 2:04:58 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Files European Application and Obtains Orphan Drug Status for PHOTOBARR (photodynamic therapy - porfimer sodium) newswire.ca

To: Arthur Radley who wrote (494)	4/22/2002 2:23:58 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Completes the Acquisition of Laboratoire du Lactéol du Docteur Boucard in France newswire.ca

To: Arthur Radley who wrote (494)	4/29/2002 8:55:13 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Pharma to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York newswire.ca

To: Arthur Radley who wrote (494)	5/7/2002 11:11:36 AM
From: Al Collard	Read Replies (1) \| Respond to of 1590

Axcan's Second Quarter Earnings Increase 30% Revenues Rise 24% newswire.ca

To: Arthur Radley who wrote (494)	5/23/2002 5:50:06 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan and Nicox Sign A Co-Development and License Agreement For A Nitric Oxide Ursodiol Derivative For The Treatment Of Chronic Liver Diseases, Including Portal Hypertension And Hepatitis C newswire.ca

To: Arthur Radley who wrote (494)	5/29/2002 2:29:18 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Pharma Inc. - URSO 500 mg Tablets Approved in Canada for the Treatment of Cholestatic Liver Diseases newswire.ca

To: Arthur Radley who wrote (494)	7/4/2002 10:52:45 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: The Solidarity Fund QFL Invests in Axcan newswire.ca

To: Arthur Radley who wrote (494)	8/2/2002 4:43:36 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Announces Positive Results of Studies on the Use of Ursodiol in the Prevention of the Recurrence of Colorectal Adenomatous Polyps newswire.ca

To: Arthur Radley who wrote (494)	8/14/2002 8:23:56 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Receives Non Approval Letter for Helicide - The Company intends to respond to FDA issues by October 31, 2002 newswire.ca

To: Arthur Radley who wrote (494)	10/2/2002 1:57:41 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan to Broaden its 5-ASA Product Line newswire.ca

To: Arthur Radley who wrote (494)	10/10/2002 8:39:45 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Acquires Rights to Rectal Gel Mesalamine Preparation to Expand its North American Product Line newswire.ca

To: Arthur Radley who wrote (494)	10/30/2002 9:02:13 AM
From: Al Collard	Read Replies (1) \| Respond to of 1590

AXP-t...in the news: Axcan Responds to FDA Questions on Manufacturing Issues for HELICIDE newswire.ca

To: Arthur Radley who wrote (494)	11/14/2002 5:35:25 PM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Delivers Record Performance for Fiscal 2002- Sales up 27% to $133 Million and Net Earnings up 82% to $20.9 Million newswire.ca

To: Arthur Radley who wrote (494)	12/3/2002 6:12:17 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Axcan Receives an Approvable Letter from the FDA for PHOTOFRIN - Final Approval is Expected in the Next Few Months newswire.ca

To: Arthur Radley who wrote (494)	12/4/2002 6:23:19 AM
From: Al Collard	Respond to of 1590

AXP-t...in the news: Globe says Axcan swallowing Abbott's Panzytrat brand The Globe and Mail reports in its Wednesday, Dec. 4, edition that Axcan Pharma has struck a deal to acquire a line of drug products from Abbott Laboratories of North Chicago, Ill. The Globe's Briefing column reports that under a deal announced Tuesday, Axcan will acquire a pancreatic enzyme line of products under the Panzytrat brand name from Abbott for $45-million (U.S.) in cash. Axcan, based in Mont St-Hilaire, Que., said it expects the acquisition to increase its revenue and add about eight U.S. cents a share in profit over the next year. Axcan stock slipped a Canadian dime to close at $17 (Canadian) on the Toronto Stock Exchange Tuesday. The stock has a 52-week trading range of $24.23 (Canadian) to $12.33 (Canadian).